Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)

• Status: Unknown status
• Trial end date: 2004-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and efficacy of DN-101 (calcitriol) in patients with myelodysplastic syndrome who are dependent on repeat blood transfusions.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novacea
• Treatments: Calcitriol

Criteria

• Diagnosis of low or intermediate-1 risk MDS

• Dependent on monthly blood transfusions

• No cancer within the last 5 years (cured skin cancer is allowed)

• No heart attack or stroke within the last 6 months

• No kidney stones within the last 5 years